PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

This study is testing whether adding a PD-1 immunotherapy drug to the standard chemoradiation treatment improves outcomes for women with locally advanced cervical cancer (stages IB2–IIIB). PD-1 inhibitors help the immune system recognize and attack cancer cells. **You may be eligible if...** - You are a woman aged 18 or older with cervical cancer confirmed by biopsy (squamous cell, adenocarcinoma, or adenosquamous type, stages IB2–IIIB) - You have not received any prior treatment for cervical cancer (no radiation, chemotherapy, or other systemic therapy) - You have measurable tumor lesions - Your general health is good enough for treatment (ECOG 0–2) - Your expected survival is greater than 6 months - Women of childbearing age agree to use contraception during and for 6 months after treatment **You may NOT be eligible if...** - You have severe organ dysfunction or lab values outside the protocol range - You are pregnant or unable to comply with study requirements Talk to your doctor to see if this trial is right for you.